| review article | Q7318358 |
| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1050157198 |
| P356 | DOI | 10.2165/00003495-200262170-00002 |
| P698 | PubMed publication ID | 12421100 |
| P2093 | author name string | Mohammed H Moghadasian | |
| P2860 | cites work | Use of statins and the subsequent development of deep vein thrombosis | Q28184655 |
| Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) | Q29547825 | ||
| The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators | Q29547887 | ||
| Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group | Q29615228 | ||
| C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women | Q29616306 | ||
| Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study | Q29617822 | ||
| Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol Levels | Q29620696 | ||
| Anti-oxidative properties of fluvastatin, an HMG-CoA reductase inhibitor, contribute to prevention of atherosclerosis in cholesterol-fed rabbits | Q31798151 | ||
| Beneficial effects of pravastatin in peri- and postmenopausal hyperlipidemic women: a 5-year study on serum lipid and sex hormone levels | Q31926200 | ||
| An HMG-CoA reductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metalloproteinases and tissue factor in vivo and in vitro | Q32033463 | ||
| The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals | Q33688733 | ||
| Clinical pharmacology of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors | Q33742346 | ||
| The evolving role of statins in the management of atherosclerosis | Q33818141 | ||
| Statins and bones | Q33955458 | ||
| Effects of HMG-CoA reductase inhibitor on hemostasis | Q34106488 | ||
| Pharmacotherapy of hypercholesterolaemia: statins in clinical practice | Q34182077 | ||
| Menopause and the risk of coronary heart disease in women | Q34184268 | ||
| 17 beta-Estradiol attenuates acetylcholine-induced coronary arterial constriction in women but not men with coronary heart disease | Q34313559 | ||
| Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors | Q34463540 | ||
| Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators | Q78017116 | ||
| Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence | Q34748119 | ||
| Oestradiol inhibits smooth muscle cell proliferation of pig coronary artery | Q36329492 | ||
| Platelet reactivity and arachidonic acid metabolism in type II hyperlipoproteinaemia and its modification by cholesterol-lowering agents | Q37825262 | ||
| Design of the Women's Health Initiative clinical trial and observational study. The Women's Health Initiative Study Group | Q39513392 | ||
| Molecular bases of the acute coronary syndromes | Q40530238 | ||
| Hormonal treatment of postmenopausal women | Q40724769 | ||
| Inhibitory effect of fluvastatin, an HMG-CoA reductase inhibitor, on the expression of adhesion molecules on human monocyte cell line | Q41152300 | ||
| Efficacy and tolerability of lovastatin in 3390 women with moderate hypercholesterolemia | Q42558556 | ||
| Women's health study signs up millionth woman | Q42558911 | ||
| Use of statins and risk of fractures | Q43531106 | ||
| Fluvastatin lowers atherogenic dense low-density lipoproteins in postmenopausal women with the atherogenic lipoprotein phenotype | Q43578102 | ||
| Aggressive versus moderate lipid-lowering therapy in postmenopausal women with hypercholesterolemia: Rationale and design of the Beyond Endorsed Lipid Lowering with EBT Scanning (BELLES) trial | Q43587089 | ||
| Effects of bezafibrate and simvastatin on plasma lipoproteins in hypercholesterolemia resistant to hormone replacement therapy | Q43612137 | ||
| Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events | Q43656468 | ||
| Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the nurses' health study | Q43776201 | ||
| Estrogen/progesterone replacement versus pravastatin and their sequential association in hypercholesterolemic postmenopausal women | Q43814234 | ||
| Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS): efficacy and tolerability of long-term treatment with lovastatin in women | Q43852393 | ||
| A comparison of continuous combined hormone replacement therapy, HMG-CoA reductase inhibitor and combined treatment for the management of hypercholesterolemia in postmenopausal women | Q43856931 | ||
| Statin attenuates increase in C-reactive protein during estrogen replacement therapy in postmenopausal women | Q43943280 | ||
| Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins | Q44181135 | ||
| Effects of age, sex, and menopausal status on plasma lipoprotein(a) levels. The Framingham Offspring Study. | Q51060020 | ||
| The effect of hormone replacement therapy alone and in combination with simvastatin on plasma lipids of hypercholesterolemic postmenopausal women with coronary artery disease. | Q51566961 | ||
| Estrogen and progestin compared with simvastatin for hypercholesterolemia in postmenopausal women. | Q51573778 | ||
| HMG-CoA reductase inhibition improves endothelial cell function and inhibits smooth muscle cell proliferation in human saphenous veins | Q54888399 | ||
| The Use of Estrogens and Progestins and the Risk of Breast Cancer in Postmenopausal Women | Q57752001 | ||
| Platelet Deposition on Eroded Vessel Walls at a Stenotic Shear Rate Is Inhibited by Lipid-Lowering Treatment With Atorvastatin | Q60924263 | ||
| Guidelines for counseling postmenopausal women about preventive hormone therapy. American College of Physicians | Q67587287 | ||
| The lowering of lipoprotein[a] induced by estrogen plus progesterone replacement therapy in postmenopausal women | Q70460348 | ||
| Hormone replacement therapy and serum angiotensin-converting-enzyme activity in postmenopausal women | Q71852030 | ||
| Single LDL apheresis improves endothelium-dependent vasodilatation in hypercholesterolemic humans | Q71971748 | ||
| Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial | Q72375182 | ||
| Oestrogen and inhibition of oxidation of low-density lipoproteins in postmenopausal women | Q72665668 | ||
| Sex hormones and lipoprotein metabolism | Q72786262 | ||
| Plasma lipid, lipoprotein cholesterol, and apoprotein distributions in selected US communities. The Atherosclerosis Risk in Communities (ARIC) Study | Q72862072 | ||
| Hormone replacement and simvastatin in the therapy of hypercholesterolemic postmenopausal women | Q73033492 | ||
| Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month | Q73120271 | ||
| Effects of simvastatin only or in combination with continuous combined hormone replacement therapy on serum lipid levels in hypercholesterolaemic post-menopausal women | Q73365039 | ||
| Sex-related differences in response of plasma lipids to simvastatin: the Saitama Postmenopausal Lipid Intervention Study. S-POLIS Group | Q73381703 | ||
| A comparison of estrogen replacement, pravastatin, and combined treatment for the management of hypercholesterolemia in postmenopausal women | Q73414829 | ||
| Effects of combination therapy with estrogen plus simvastatin on lipoprotein metabolism in postmenopausal women with type IIa hypercholesterolemia | Q73712789 | ||
| Bezafibrate and simvastatin combination therapy for diabetic dyslipidaemia: efficacy and safety | Q73789865 | ||
| Effects of simvastatin or hormone replacement therapy, or both, on fibrinogen, factor VII, and plasminogen activator inhibitor levels in postmenopausal women with proven coronary artery disease | Q73924556 | ||
| A randomized placebo-controlled trial of fluvastatin for prevention of restenosis after successful coronary balloon angioplasty; final results of the fluvastatin angiographic restenosis (FLARE) trial | Q74601678 | ||
| Effect of estrogen and simvastatin on low-density lipoprotein subclasses in hypercholesterolemic postmenopausal women | Q77167955 | ||
| Individual and combined effects of estrogen/progestin therapy and lovastatin on lipids and flow-mediated vasodilation in postmenopausal women with coronary artery disease | Q77853741 | ||
| Vascular effects of estrogen and cholesterol-lowering therapies in hypercholesterolemic postmenopausal women | Q77905025 | ||
| P433 | issue | 17 | |
| P304 | page(s) | 2421-2431 | |
| P577 | publication date | 2002-01-01 | |
| P1433 | published in | Drugs | Q3040094 |
| P1476 | title | Statins and menopause | |
| P478 | volume | 62 |
Search more.